WASHINGTON, DC – Food Marketing Institute (FMI) today participated in the Food and Drug Administration’s (FDA) public hearing regarding products containing cannabis or cannabis-derived compounds, including hemp and cannabidiol (CBD), as the agency considers whether and how to create a legal pathway for such products. FMI both conveyed the seriousness of the regulatory ambiguity facing its member companies and their shoppers amidst the momentum of these products in the marketplace, and also appealed to FDA for additional clarity.
↧